![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
For the third quarter of 2022 earnings season HGEN decreased a loss per share of $-0.23 per share compare to $-1.12 a year ago and EPS improved from $-0.43 per share from the prior reporting season.
Revenues fell sharply by -78.668 % to $
0.22 millions from $1.04 millions in the corresponding reporting season a year ago and sequentially Revenue Tumbled by -78.668 % from $1.04 millions.
In the third quarter of 2022 earnings season Humanigen Inc reported net loss of $-23.693 million, instead of deficit of $-66.739 millions in the corresponding reporting season a year ago.
Humanigen Inc is expected to report next financial results on February 27, 2023.